...
首页> 外文期刊>Journal of Molecular Diagnostics >Quantitative PCR Detection of t(14;18) bcl-2/JH Fusion Sequences in Follicular Lymphoma Patients Comparison of Peripheral Blood and Bone Marrow Aspirate Samples
【24h】

Quantitative PCR Detection of t(14;18) bcl-2/JH Fusion Sequences in Follicular Lymphoma Patients Comparison of Peripheral Blood and Bone Marrow Aspirate Samples

机译:滤泡性淋巴瘤患者t(14; 18)bcl-2 / JH融合序列的定量PCR检测比较外周血和骨髓抽吸物样本

获取原文
获取原文并翻译 | 示例
           

摘要

In patients with follicular lymphoma (FL), it is unresolved whether peripheral blood (PB) can replace bone marrow (BM) aspirate samples for detection of bcl-2/JH fusion sequences that result from the t(14;18)(q32;q21). We compare here the results of quantitative polymerase chain reaction (q-PCR) analysis for bcl-2/JH involving the major breakpoint cluster region (mbr) on paired PB and BM aspirate samples from 60 consecutive FL patients. There was a significant correlation between the level of bcl-2/JH fusion sequence obtained from PB and BM aspirate samples (r = 0.886), with 82% of samples showing less than one log of difference. Patients who had histological evidence of FL involving concurrent BM biopsy specimens had moderate to high levels of bcl-2/JH in both PB and BM aspirate samples, allowing unequivocal determination of translocation status (median bcl-2/JH to cyclophilin level was 8.014%). In contrast, patients with no detectable FL in their BM biopsy specimens often showed low levels of bcl-2/JH in both PB and BM aspirate samples (bcl-2/JH to cyclophilin median level = 0.006%), in a range similar to background levels that could be detected in patients without FL (n = 15, median bcl-2 mbr/JH to cyclophilin level = 0.002%). We conclude that PB can be used in place of BM aspirate samples to test for the presence of bcl-2 mbr/JH fusion sequence in FL patients and that either PB or BM aspirate testing yields a rough approximation of the degree of BM involvement by FL. However, in patients with minimal levels of bcl-2/JH in PB or BM aspirate samples, confirmation of this result by testing the primary tumor is recommended to confirm the presence of an identical bcl-2/JH fusion sequence and exclude false-positive results.
机译:在滤泡性淋巴瘤(FL)患者中,是否可以用外周血(PB)代替骨髓(BM)抽吸样品来检测由t(14; 18)(q32;)产生的bcl-2 / JH融合序列尚无定论。 q21)。我们在这里比较bcl-2 / JH定量聚合酶链反应(q-PCR)分析的结果,该bcl-2 / JH涉及来自60位连续FL患者的成对PB和BM抽吸样本的主要断点簇区域(mbr)。从PB和BM抽吸样品获得的bcl-2 / JH融合序列水平之间存在显着相关性(r = 0.886),其中82%的样品显示差异小于1 log。有组织学检查结果并发BM活检标本的FL患者在PB和BM抽吸样品中都有bcl-2 / JH的中度至高水平,因此可以明确确定易位状态(bcl-2 / JH中位至亲环蛋白水平为8.014% )。相反,在BM活检标本中未检测到FL的患者,在PB和BM抽吸样本中经常显示出低水平的bcl-2 / JH(bcl-2 / JH至亲环蛋白中位水平= 0.006%),其变化范围与无FL患者可以检测到的背景水平(n = 15,中环bcl-2 mbr / JH至亲环蛋白水平= 0.002%)。我们得出的结论是,PB可以代替BM抽吸样品来检测FL患者中bcl-2 mbr / JH融合序列的存在,并且PB或BM抽吸测试可以粗略估计FL所累及的BM程度。然而,在PB或BM抽吸样品中bcl-2 / JH水平最低的患者中,建议通过测试原发肿瘤来确认该结果,以确认存在相同的bcl-2 / JH融合序列并排除假阳性结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号